2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Frailty
12
Neoplasms
11
Ovarian Neoplasms
5
Lymphoma
5
Lung Neoplasms
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Treatment Adherence and Compliance
1
Stomach Neoplasms
1
Solid Neoplasm
1
Sarcopenia
1
Sarcoma
1
Recurrence
1
Prostate Cancer Cured
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Geriatric Assessment
×
Clear all
NCT04113226
2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2
Unknown
114 enrolled